Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Vaccine Adjuvant. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN113527382B reveals a novel MPLA synthesis route using Nap protection. Achieve higher purity and cost reduction in vaccine adjuvant manufacturing with scalable methods.
Patent CN113527050B reveals a novel Nap-protected MPLA intermediate synthesis. This method eliminates hydrogenation, ensuring high purity and scalable supply for vaccine adjuvant manufacturing.
Novel allyl phosphate route for MPLA intermediates ensures high purity and scalable supply chain for pharmaceutical manufacturing partners seeking reliable vaccine adjuvant solutions.